China Digest: BangEr, Cothera, MAKE ESSENSE in funding news Premium
Chinese specialized hospital chain operator BangEr Orthopedic, anti-tumour drug developer Cothera Bioscience, and men’s skincare brand MAKE ESSENSE have raked in new financing to expand operations.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday
REGISTER stories left placeholder You have one free story left this month. You have stories left placeholder free stories left this month. This is your last free story of the month.
streetAsia s premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. SUBSCRIBE NOW
Singapore Reporter/s
In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digi
Qiming leads new funding in Fushoukang and 10 more deals from Greater China ResearchPremium
Shanghai-headquartered home care services platform Fushoukang has raised ‘tens of millions of US dollars’ in a Series B round led by Qiming Venture Partners, per a company statement on Tuesday.
New investor Beijing Tonglong Capital Management along with return backer Fortune Capital also joined the round.
China Renaissance facilitated the transaction.
Fushoukang claims to hold a 30 per cent market share in Shanghai, serving over 10 million stay-at-home elderly people in 2020.
The company will use the capital for business development across China, platform innovation and commercialisation of personalised services.